We're Building the Future of Metabolic Therapeutics
Inspired by the dramatic metabolic improvements with bariatric surgery, we're a team of scientists, clinicians, and business leaders with the passion, technical vision, and therapeutic expertise to deliver these metabolic benefits in an oral therapy.
Our Mission
To transform the treatment of type 2 diabetes and obesity with a non-systemic, well-tolerated oral therapy that shifts nutrient sensing from the upper to the lower GI tract — delivering improved glycemic control and weight loss without surgery or injections.
Why We Exist
The world is in the middle of a diabetes and obesity crisis.
Incretins (GLP-1s and GIPs) have improved upon previous standard-of-care, but they haven't solved the problem.⁴
- Discontinuation rates remain high
- Many patients can't tolerate injectable medications
- Side effects such as nausea and vomiting
- A lack of glycemic control, and/or
- Access challenges to therapy.
At AltrixBio, we're committed to providing better therapeutic solutions for people with diabetes and obesity, and we've taken a fundamentally different approach: AJN003, a once-daily, non-systemic oral therapy that shifts nutrient sensing from the upper GI tract triggering comprehensive metabolic changes. AJN003 represents a potential new category of treatment for type 2 diabetes and obesity.
Our leadership team combines deep scientific, clinical, and commercial expertise in launching first-in-class diabetes and metabolic treatments.
Connect With Us